Biotech Values

[dewophile]

We're yet to see if Apixaban can produce a better profile (I think it has a better shot) in this indication from this study

i think it has a better shot as well, but i still view it as a fairly high risk study given apixaban did show more bleeding than placebo in the ACS trial, so they likely are going to have to show a real efficacy benefit to justify what is likely going to be a slightly higher bleeding rate vs those who jsut take placebo after discharge from the hospital
in terms of data flow i assume ARISTOTLE will be in before this reads out, which imo is more likely to be successful - so success in this indication would be the cherry on top